摘要
目的 探讨沙美特罗替卡松吸入对哮喘合并慢性阻塞性肺疾病（COPD）急性加重期患者肺功能及炎性因子的影响.方法 选取哮喘合并COPD急性加重期的患者110例.采用随机数字表法分为观察组（55例）和对照组（55例）,对照组：常规治疗;观察组：在常规治疗的基础上加用沙美特罗替卡松吸入治疗.记录对比两组的肺功能指标、炎性因子水平与疗效评价.结果 观察组治疗后用力肺活量（FVC）、1 s用力呼吸容积（FEV1）、FEV1占用力肺活量比值（FEV1/FVC）分别为（2.64±0.45）L、（1.98±0.46）L和（80.42±6.43）％,均明显优于对照组（t=2.89、2.59、6.27,均P〈0.05）;观察组治疗后痰液中的肿瘤坏死因子α（TNF-α）、白细胞介素8（IL-8）、IL-10与IL-17水平分别为（30.03±6.78）μg/L、（59.96±7.73）μg/L、（29.89±4.11）μg/L和（92.37±9.79）μg/L,均明显低于对照组（t=7.54、6.16、7.04、12.31,均P〈0.05）,观察组治疗后外周血中的TNF-α、IL-8、IL-10与IL-17水平分别为（14.08±5.36）μg/L、（26.32±4.03）μg/L、（30.32±5.04）μg/L和（173.82±18.19）μg/L,均明显低于对照组（t=4.26、7.95、11.25、5.31,均P〈0.05）;观察组治疗有效率为94.55％,对照组为81.82％,观察组疗效评价明显优于对照组（P〈0.05）.结论 沙美特罗替卡松吸入可改善患者肺功能,降低患者痰液和外周血中的炎性因子水平,值得临床推广应用.
Objective To investigate the effect of salmeterol fluticasone inhalation on pulmonary function and inflammatory cytokines in patients with acute exacerbation of chronic obstructive pulmonary disease （ COPD ） . Methods 110 patients with acute exacerbation of asthma combined with COPD were selected and divided into observation group （55 cases） and control group （55 cases） by the random number table .The control group was given conventional treatment ,while the observation group was given salmeterol fluticasone inhalation therapy on the basis of routine treatment .The pulmonary function ,inflammatory cytokines and curative effects were compared between the two groups.Results After treatment,the FVC,FEV1,FEV1/FVC of the observation group were （2.64 ±0.45） L, （1.98 ±0.46）L and （80.42 ±6.43）%,which were significantly better than those of the control group （t=2.89, 2.59,6.27,all P〈0.05）,the improvement of lung function was more obvious than that of the control group （P〈0.05）.After treatment,the levels of TNF-α,IL-8,IL-10 and IL-17 in sputum of the observation group were （30.03 ±6.78）μg/L,（59.96 ±7.73）μg/L,（29.89 ±4.11）μg/L and （92.37 ±9.79）μg/L,respectively,which were significantly lower than those of the control group （t=7.54,6.16,7.04,12.31,all P〈0.05）.After treatment, the levels of TNF -α, IL -8, IL-10 and IL -17 in peripheral blood of the observation group were （ 14.08 ± 5.36）μg/L,（26.32 ±4.03）μg/L,（30.32 ±5.04）μg/L and （173.82 ±18.19）μg/L,respectively,which were significantly lower than those of the control group （t =4.26,7.95,11.25.5.31,all P〈0.05）.The decrease of inflammatory cytokines in sputum and peripheral blood of the observation group was more significant than that of the control group （P〈0.05）.The effective rate of the observation group was 94.55%,which was significantly higher than 81.82%of the control group （P〈0.05）.Conclusion Salmeterol fluticasone inhalation can improve patients＇pulmonary
出处
《中国基层医药》
CAS
2018年第3期375-378,共4页
Chinese Journal of Primary Medicine and Pharmacy
关键词
哮喘
肺疾病
慢性阻塞性
肺功能
炎性因子
沙美特罗替卡松
Asthma
Pulmonary disease, chronic obstructive
Pulmonary function
Inflammatory factor
Salmeterol fluticasone
